Agios Pharmaceuticals Inc. News
Agios Soars on Plan to Sell Cancer Drugs, Return $1.2B to Holders
Drugmaker Agios soared on a plan to sell an oncology portfolio to Servier for up to $2 billion and return $1.2 billion to shareholders.
Celgene, Agios Update Blood Cancer Drug Study Results in ASCO '17 Abstract
The new enasidenib data -- improved tumor response rate but shorter duration -- were made public on Wednesday night in a research abstract.
4 Health Care Charts Signaling Buys: Pfizer, Amgen Included
Obamacare? Trumpcare? These stocks don't care.
Biotechs Among 5 Stocks Setting Up for Major Breakouts
Here's how to rake in the profits off some potential big breakouts.
Analysts' actions: Chipotle, Disney, Brinker, JPMorgan and more
Here are Tuesday's top research calls, including upgrades for Disney, Continental Resources and Agios Pharmaceuticals, and downgrades for Chipotle, Brinker International and JPMorgan Chase.
Agios Shelves Rare Anemia Disorder Drug Due to Liver Toxicity, Switches to Backup
Agios owns the full rights to both drugs in the PKD development program, which makes them particularly important to the company.
Agios blood cancer drug heading to early FDA filing by partner Celgene
Celgene owns the rights to the Agios drug known as AG-221 under an existing partnership.
Agios Pharmaceuticals (AGIO) Highlighted As Weak On High Volume
Trade-Ideas LLC identified Agios Pharmaceuticals (AGIO) as a weak on high relative volume candidate
Trump's Potential Return to Twitter Under Musk Hits Digital World
Digital World Acquisition, a company attempting to merge with former President Donald Trump's media group Truth Social, faces a new challenge.
Bluebird Bio's 2nd Approval Doesn't Guarantee Survival
Investors hoping for a revival at the struggling biotech might want to temper their expectations.